Page 49 - MemoriaEHD-Eng

www.ciberehd.org

• a J, F J, p v, s a, C M, p M. Relative adrenal insuffi-
Most relevant CeveDoerNáNDezraDoiLvaastroavesi
ciency in decompensated cirrhosis: Relationship to short-term risk of severe sepsis,
scientific hepatorenal syndrome, and death.Hepatology. 2013 Nov;58(5):1757-65.

articles
• reiCheNBaCh v, Muñoz-LuQue J, ros J, CasaLs g, Navasa M, FerNáNDez-varo g. Bacterial
lipopolyshaccaride inhibits CB2 receptor expression in human monocytic cells.Gut.

2013 Jul;62(7):1089-91.

• pauta M, rotLLaN N, vaLes F, FerNáNDez-herNaNDo a, aLLeN rM, ForD Da. Impaired liver
regeneration in Ldlr-/- mice is associated with an altered hepatic profile of cytokines,

growth factors, and lipids.J Hepatol. 2013 Oct;59(4):731-7.

• garCía-aLoNso v, López-viCario C, titos e, MoráN-saLvaDor e, goNzáLez-périz a, rius B.
Coordinate functional regulation between microsomal prostaglandin E synthase-1

(mPGES-1) and peroxisome proliferator-activated receptor γ (PPARγ) in the conver-
sion of white-to-brown adipocytes.J Biol Chem. 2013 Sep 27;288(39):28230-42.

• F C, B r, g M, g e, s e, r e. A modified acute kid-
aguNDesarretouevaraarCíaoLàoDríguez
ney injury classification for diagnosis and risk stratification of impairment of kidney

function in cirrhosis.J Hepatol. 2013 Sep;59(3):474-81.

Highlights
We have investigated anti-angiogenic agents with therapeutic effectiveness but
which specifically inhibit hepatic pathological angiogenesis, we have also investi-

gated the role of the receptor of low density lipoprotein in liver regeneration.

We are investigating the development of noninvasive methods that can accurately

predict the early stage of the disease and fibrosis progression in time is a priority
and growing medical need. Serum levels of several biochemical markers of colla-

gen metabolism have been shown to be useful in diagnosis of liver fibrosis.

The Group is focusing on the identification of biochemical markers and their incor-

poration into the daily routine, which will probably replace in the near future inva-
sive markers of liver fibrosis; consequently improving the diagnosis and treatment

of patients with chronic hepatitis.

The group has actively participated in the CLIF Consortium leading the first stu-
dy of the Consortium which as a result as defined Acute-on chronic Liver failure

(ACLF)asanewentity, andhascontinuedworkinginnewaspectsregardingthe

pathophysiology, clinical implications and prognosis of ACLF.

A further area of research has been the use of new biomarkers in the diagnosis
ofrenalfailureanditsprognosisinpatientswithlivercirrhosis. Afurtherlinehas

been the evaluation of new strategies for the treatment of Hepatorenal Syndrome.

13
20
T
OR
P
RE
L
A
NU
N
A
D /
H
E
ER
IB
C

49